nderstanding the relationship of host gut microbiota and immune response to patients outcome in Melioidosis

Not Applicable

• Conditions: Health Condition 1: A488- Other specified bacterial diseases

• Registration Number: CTRI/2020/06/025663
• Lead Sponsor: Indian Council of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

All melioidosis cases with or without comorbidities (diabetes, alcoholism, renal disease etc.).

Individuals having no signs and symptoms of fever, pneumonia, abscess, lymphadenitis and no past history of hospitalization for last 3 months.

Exclusion Criteria

Pregnant women.

Individuals with disease like arthritis, malignancy and on immunosuppressive therapy. The patients with above mentioned chronic diseases might have a negative impact that giving to a false positive result in seroprevalence study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This study will provide information about the difference in the gut microbiota among localized versus disseminated infection.The changes in abundance of gut microbiota between melioidosis cases and seropositive individual. <br/ ><br>The influence of long-term antibiotic treatment on the abundance of gut microbiots in patients.Timepoint: 2020-2023. <br/ ><br>Gut microbiota analysis with Journal publication-2020-2021. <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
The differences in cytokine expression of disseminated versus localized melioidosis with prognosis and outcome of patients having comorbiditiesTimepoint: Cytokine analysis with journal publications - 2021-2023.